Cambrex Corporation (NYSE:CBM) CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the sale, the chief executive officer now owns 87,328 shares in the company, valued at $4,799,546.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Cambrex Corporation (NYSE CBM) traded up 0.18% during midday trading on Tuesday, hitting $55.10. The stock had a trading volume of 441,535 shares. The company has a market cap of $1.80 billion, a P/E ratio of 20.07 and a beta of 2.28. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The firm has a 50 day moving average of $52.54 and a 200-day moving average of $55.32.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting analysts’ consensus estimates of $0.76. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share. On average, analysts forecast that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/03/cambrex-corporation-cbm-ceo-sells-219840-00-in-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Cambrex Corporation by 0.5% during the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after buying an additional 20,652 shares during the period. Vanguard Group Inc. raised its position in shares of Cambrex Corporation by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock worth $172,799,000 after buying an additional 139,010 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Cambrex Corporation by 0.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock worth $79,483,000 after buying an additional 11,762 shares in the last quarter. Congress Asset Management Co. MA raised its position in shares of Cambrex Corporation by 8.7% during the 2nd quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock worth $77,497,000 after buying an additional 103,900 shares in the last quarter. Finally, FMR LLC raised its position in shares of Cambrex Corporation by 19.1% during the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after buying an additional 171,559 shares in the last quarter. Hedge funds and other institutional investors own 98.28% of the company’s stock.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub cut shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Cambrex Corporation has a consensus rating of “Hold” and an average price target of $64.00.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.